BioWorld

Nov. 18, 2003

View Archived Issues

GenPath, Merck Sign Potential $100M Deal For Cancer Drugs

Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, excluding royalties. (BioWorld Today) Read More

Allos Presents RSR13 Data; NDA Completion Expected This Year

Read More

Anadys Files $86.25M IPO; HCV Drug Duo Leads Pack

Read More

MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi

Read More

Correction

Read More

Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review

Read More

Other News To Note

Read More